Orally active fraction of momordica charantia, active...

Details Orally active fraction of momordica charantia, active... Orally active fraction of momordica charantia, active...

2000-07-31

2002-05-21

Weber, Jon P. (Department: 1651)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S015800, C514S016700, C530S326000, C530S327000, C530S329000, C424S777000

Reexamination Certificate

active

06391854

ABSTRACT:

TECHNICAL FIELD
The field of this invention is diabetes.
BACKGROUND OF THE INVENTION
Non insulin dependent diabetes mellitus (NIDDM or Type II) is the fourth-leading cause of death in the United States and affects from 5 to 7% of the total world population, with an increasing prevalence in western countries. In diabetes, the body either does not produce enough insulin or the insulin which is produced is not effective, resulting in increased blood glucose level, a condition technically known as hyperglycemia. Although diabetes can affect people of any age, the majority of diabetics are over 45 years old. The disease tends to run in families, and the risk factor of acquiring the disease increases in overweight individuals.
Diabetes is a chronic disease with no cure and is linked with several other disorders. It is the leading cause of blindness in people ages 25-74. Ten percent of all people with diabetes develop kidney disease. Diabetes is the most frequent cause of non-traumatic lower limb amputation. The risk of leg amputation is 30 times greater for people with diabetes. People with diabetes are two to four times more likely to develop heart diseases, and are five times more likely to suffer from stroke.
The cause of diabetes is still a mystery, although both genetics and environment appear to play a role. There are two types of diabetes: Insulin dependent (Type I) and Non-insulin dependent (Type II). Type I diabetes is an autoimmune disease frequently occurring in children and young adults. The autoantigen responsible for triggering Type I diabetes is still unknown and patients have to take i.v. insulin daily to survive for their life.
Type II diabetes is a metabolic disorder resulting from the body's inability to make a sufficient amount of insulin or to properly use the insulin that it does produce, and is considered the most common form of the disease. Although insulin secretion and insulin resistance are considered the major defects, the precise genetic factors involved remain unknown. Patients with diabetes usually have one or more of the following defects. These are: less production of insulin by the pancreas; oversecretion of glucose by the liver; impairment of glucose uptake by the skeletal muscle; defects in glucose transporters (Glut-1, Glut-4); desensitization of insulin receptors; and defect in the metabolic breakdown of polysaccharides.
The current therapy utilizes four classes of oral hypoglycemic agents besides i.v. insulin. These are summarized below:
Approved
Mechanisms
Class
Drugs
of Action
Limitations
Sulfonylureas
4 (1st gen.)
Acts on pancreas
Resistance develop-
2 (2nd gen.)
to release more
ment
insulin
Biguanides
Only one
Reduces glucose
Liver problem
(metformin)
secretion by liver.
Lactic acidosis
Also improves in-
sulin sensitivity.
&agr;-Glucosidase
Only one
Interferes with
Only at postprandial
Inhibitor
(acarbose)
digestive process.
level.
Reduces glucose
absorption.
Thiazolidine-
Only one
Reduces insulin
“Add-on” with insulin
dione
(troglita-
resistency
Not for people with
zone)
heart and liver disease.
As is apparent from the above table, each of the current agents available for use in the treatment of diabetes has certain disadvantages. Accordingly there is continued interest in the identification and development of new agents for use in the treatment of diabetes.
M.charantia
is a tropical plant whose fruits are used as a vegetable. Several groups have reported on the hypoglycemic activity of
M.charantia
, both in mammal models (Shibib et al., biochem. J., 292, 267-270 (1993); Ali et al., Planta Med. 59, 408-412 (1993); Akhtar et al., Planta Med. 42, 205-212 (1981)) and in humans (Leatherdale et al., Br. Med. J. 282, 1823-1824 (1981); Aslam et al, Lancet, I. 607 (1979)). However, the hypoglycemic component and the mechanism of action remains unknown.
The isolation of an 11 kDal peptide obtained from
M.charantia
having insulin like activity is reported in: Khanna et al., “Hypoglycemic Activity of Polypeptide-p from a Plant Source,” 20th Annual Meeting of the American Society of Pharmacology, Purdue University, West Lafayette, Jul. 29-Aug. 3, 1979; Baldwa et al., Upsala J. Med. Sci. (1977) 82:39-41 and U.S. Pat. No. 3,945,989. In all of these reports, the insulin like polypeptide was non-orally administered. e.g, i.v. or subcutaneously.
A recent report indicates that the crude alcoholic extract of
M.charantia
lowers plasma glucose level partly by stimulation of glycogen synthesis in the liver and it is unlikely that it acts as an insulin secreting agent (Sarkar et al. Pharmacol. Res., 33. 1-4 (1996)).
SUMMARY OF THE INVENTION
A water soluble fraction of
M.charantia
(MC6) and methods for its preparation and use in the treatment of hyperglycemic disorders are provided. MC6 is characterized by migrating as a single band on SDS-PAGE electrophoresis having a molecular weight of less than 10 kDal, having a size smaller than recombinant insulin, comprising three peptides, and being free of high molecular weight protein contaminants. Also provided is a specific peptide component of MC6, labeled MC6.1 and peptide derivatives of MC6.1 which are shorter in length an MC6.1, MC6.2 and MC6.3, which exhibit hypoglycelic activity and may be administered orally to treat a variety of hyperglycemic disorders.


REFERENCES:
patent: 3817837 (1974-06-01), Rubenstein et al.
patent: 3850752 (1974-11-01), Schuurs et al.
patent: 3853914 (1974-12-01), Goldstein
patent: 3905654 (1975-09-01), Tribe
patent: 3945988 (1976-03-01), Khann et al.
patent: 4043989 (1977-08-01), Schneider et al.
patent: 4069105 (1978-01-01), Singh et al.
patent: 4156081 (1979-05-01), Singh et al.
patent: 4368149 (1983-01-01), Masuho et al.
patent: 4985248 (1991-01-01), Liu
patent: 5086043 (1992-02-01), Liu
patent: 5098710 (1992-03-01), Liu
Stahl et al., Biochem., 32:1991-2002 (1993).
Rudinger “Peptide Hormones”, Parsons J.A., editor (1976) (Univ. park press: Baltimore, MD) p. 1-7.
Akhtar et al, Planta Med., 42:205-212 (1981).
Ali et al, Planta Med., 59:408-412 (1993).
Aslam et al, Lancet, 1:607 (1979).
Baldwa et al, Upsala J. Med. Sci., 82:39-41 (1977).
DiColo, Biomaterials, 13:850-856 (1992).
Driscoll et al, J. Mol. Bio., 232:342-350 (1993).
Dubey et al, Fitoterapia, 58(6):387-39 (1987).
El-Gengaihi et al, Bull. Natl. Res. Cent., 21(3):269-276 (1996).
Hales et al, Biochem. J., 88:137 (1963).
Harrison's “Principles of Internal Medicine”, 11th ed., Braunwald et al, ed., McGrall Hill Book Co, NY 1987.
Heller, CRC Critical Reviews in Therapeutic Drug Carrier Systems, vol. 1, “Biogradable Polymers in Controlled Drug Delivery”, CRC Press, Boca Raton, FL, pp 39-60 (1987).
Kadish et al, Clin. Chem., 14:116 (1968).
Karunanayake et al, J. Ethnopharmacol., 11(2):223-232 (1984).
Khanna et al, J. Natural Products, 42(6):684 (1979).
Khanna et al, “Hypoglycemic Activity of Polypeptide-p from a Plant Source”, 20th Annual Meeting of the American Society of Pharmacoloby, Purdue Univ., West Lafayette, Jul 29-Aug. 3, 1979 in J. Nat. Prod, (1981) 44(6), 648-655.
Ng et al, The American J. Of Chinese Medicine, 15 (1-2):31-42 (1987).
Oijua et al, J. Tradit. chin. Med., 52(2):99-106 (1985).
Pugazhenthi et al, Indian J. Clin Biochem., 11(2):115-119 (1996).
Raman et al, Phytomedicine, 2(4):349-362 (1996).
Reza-Ul-Jalil et al, J. Bangladesh Acad. Sci., 10(1):25-30 (1986).
Sambrook et al, Molecular Cloning: A Laboratory Manual, pp. V-XXXII CSHL Press, Cold Spring Harbor, NY 2nd ed. (1989).
Sarkar et al, Pharmacol. Res., 33:104 (1996).
Shibib et al, Biochem. J., 292:267-270 (1993).

Affiliated with

Also associated with

Rating

Orally active fraction of momordica charantia, active... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Orally active fraction of momordica charantia, active..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Orally active fraction of momordica charantia, active... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2866089